Imaxio sells Trolovol® (D-penicillamine) to focus on vaccines

Imaxio, a biotech company specializing in immunology announces today the sale of Trolovol® (D-penicillamine), a drug for human usage indicated for an orphan disease affecting around 1,200 patients in France. The transaction was facilitated by CMC Consulting Group.

This sale is aligned with Imaxio’s willingness to refocus its business on vaccines. This is the result of several years of work by Imaxio’s teams, which have increased Trolovol®’s turnover since its acquisition by Imaxio in May 2012. Thanks to this deal, Imaxio will now focus on the commercialization of Spirolept®, its human vaccine indicated for the prevention of a professional infectious disease, and on the development of its vaccines pipeline, based on its proprietary technology IMX313.

IMX313 is an antigen re-engineering pro-immunogenic technology which significantly improves the efficacy of vaccines with which it is used. Thanks to IMX313, Imaxio is currently developing a clinical-stage pipeline composed of several vaccine candidates indicated to prevent or treat malaria (phase I), influenza (preclinical phase), and some types of cancer (research).

Spirolept®, which is marketed in France, generates more than EUR 2 million sales. Imaxio is currently evaluating the opportunity to export the product in a European country and several emerging countries. Imaxio remains open to acquisitions or collaborations to distribute other vaccines than Spirolept in France.

“We are delighted to have finalized this transaction, which highlights the efficacy with which Imaxio’s teams have managed Trolovol® since 2012,” said Alexandre Le Vert, Chief Executive Officer of Imaxio. “This sale will enable our teams to focus exclusively on vaccines, and to work synergistically for the development of our clinical-stage vaccine pipeline based on IMX313 technology.”